Tosi G., Ruozi B., Vilella A., Grabrucker A.M., Belletti D., Vandelli M.A., Boeckers T.M., Forni F., Zoli M., Sharma A., Sharma H.S., Muresanu D.F., Sharma A., Sharma H.S.
Uppsala University, SE
Keywords: Alzheimer’s disease, nano drug delivery, nanomedicine, neurodegenerative disease
The novelty of the last 3 years of research is on the fate of NPs made of poly-lactic-co-glycolic acid (PLGA) and engineered with g7, a glycopeptide that enhances BBB crossing capability, in the living mouse brain. PLGA is a polymer used in several biomedical devices for humans, such as implants and microparticles, in view of its high biodegradability and the approval by the American Food and Drug Administration (US FDA) and European Medicine Agency (EMA).We develop multifunctional nanoparticle based on PLGA polymer engineered with ligands as i) fluorescent markers (Rhodamine) for imaging; ii) loaded drugs for therapeutic aims; iii) glycopeptide for blood-brain barrier crossing (e.g., g7 peptide; iv) antibodies (mAb) to target specific cell populations
Journal: TechConnect Briefs
Volume: 3, Biotech, Biomaterials and Biomedical: TechConnect Briefs 2015
Published: June 14, 2015
Pages: 25 - 28
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topics: Biomaterials, Materials for Drug & Gene Delivery
ISBN: 978-1-4987-4729-5